// App-Quantinova.ai

P026 : Durable Improvements in Relapse and Disability Outcomes over 7 Years with Alemtuzumab in CARE-MS II Patients: Results from the TOPAZ Study

Researchers

Presenter

  • Barry A Singer

Principal Investigators

  • Raed Alroughani

  • David Brassat

  • Simon Broadley

  • Hans-Peter Hartung

  • Eva Havrdova

  • Ho Jin Kim

  • Celia Oreja-Guevara

  • Carlo Pozzilli

  • Krzysztof W. Selmaj

  • Patrick Vermersch

  • Sibyl Wray

  • David H Margolin

  • Nadia Daizadeh

  • Madalina Chirieac

  • Alasdair J Coles

Medical Centers

  • The MS Center for Innovations in Care, Missouri Baptist Medical Center, St Louis, MO

  • 3Amiri Hospital Sharq Kuwait

  • Hematology, University Hospital of Toulouse, Toulouse, France

  • 4School of Medicine, Gold Coast Campus, Griffith University Queensland Australia

  • Heinrich-Heine-Universitat, Dusseldorf, Germany

  • Charles Univ and VFN, Prague, Czech Republic

  • 28Research Institute & Hospital of National Cancer Centre Goyang Korea, Republic of

  • University Hospital La Paz, Madrid, Spain

  • 12Medical University of Łódź Poland

  • Universite de Lille 3, Lille, France

  • Hope Neurology PLLC, Knoxville, TN

  • Sanofi, Cambridge, MA

  • University of Aberdeen School of Medicine, Aberdeen, United Kingdom

Locations

  • United States

  • Kuwait

  • France

  • Australia

  • Germany

  • Czech Republic

  • Republic of South Korea

  • Spain

  • Italy

  • Poland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Alemtuzumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT00548405

  • NCT0090553

  • NCT02255656

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved